6 These variations in results have led to investigations of drug-induced liver injury by individual DOACs in observational studies. 7-11 Nevertheless, limited data are available for edoxaban, given its comparative late entry into the international market. ...we conducted this territory-wide study to assess the risk of liver injury in edoxaban users who have no prior history of liver diseases. ...1213 edoxaban users were included (Table 1, left), with 19 developing liver injury after its prescription, which corresponded to an incidence of 1.5% (Figure 2). ...a follow-up analysis of the ENGAGE AF-TIMI 48 trial demonstrated that a history of liver disease did not significant affect the efficacy of safety of edoxaban compared to warfarin and the rates of hepatic adverse events were similar between edoxaban or warfarin users. 15 Future observational studies should examine the efficacy and safety outcomes in this specific subgroup to complement findings from this important trial.